End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
37.64 EUR | +0.82% | -0.03% | -18.79% |
06-04 | Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients | MT |
06-04 | Bristol Myers: positive results in liver cancer | CF |
Sales 2024 * | 46.09B 42.34B 62.99B | Sales 2025 * | 46.06B 42.31B 62.94B | Capitalization | 84.63B 77.75B 116B |
---|---|---|---|---|---|
Net income 2024 * | -5.41B -4.97B -7.4B | Net income 2025 * | 10.22B 9.39B 13.97B | EV / Sales 2024 * | 2.68 x |
Net Debt 2024 * | 39.03B 35.86B 53.35B | Net Debt 2025 * | 31.68B 29.1B 43.29B | EV / Sales 2025 * | 2.53 x |
P/E ratio 2024 * |
-15.9
x | P/E ratio 2025 * |
7.9
x | Employees | 34,100 |
Yield 2024 * |
5.76% | Yield 2025 * |
6.05% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
1 day | +0.82% | ||
1 week | -0.03% | ||
1 month | -7.58% | ||
3 months | -21.17% | ||
6 months | -19.57% | ||
Current year | -18.79% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
Date | Price | Change |
---|---|---|
24-06-04 | 38.35 | +0.89% |
24-06-03 | 38.01 | +0.98% |
24-05-31 | 37.64 | +0.82% |
24-05-30 | 37.34 | -0.40% |
24-05-29 | 37.48 | -0.44% |
End-of-day quote Wiener Boerse, May 30, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- BMY Stock
- BMYS Stock